Why status verification matters
Regenerative medicine is a broad field. A laboratory study, a registered clinical trial, a domestic clinical pathway and a service open to foreign patients are four different things.
The RMC five-gate standard
- Regulatory pathway: What legal or regulatory route supports the activity?
- Treating institution: Which hospital, department and medical team are responsible?
- International access: Is the current pathway open to foreign-passport patients?
- Eligibility pathway: What records, criteria, exclusions and review steps apply?
- Formal plan and pricing: Can the hospital provide a current plan and fee structure after review?
Clinical research is not a treatment package
China’s national rules effective 1 May 2026 distinguish clinical research from clinical translation and application. RMC does not market research participation as a paid treatment package.
Source hierarchy
| Tier 1 | Government, regulator, official clinical registration or formal policy source |
|---|---|
| Tier 2 | Treating hospital or responsible technology provider |
| Tier 3 | Peer-reviewed medical literature |
| Tier 4 | Commercial or competitor websites — used as leads only, not as proof |
Warning signs
- Guaranteed cure or improvement
- One product offered for many unrelated conditions
- No named treating hospital or physician
- Clinical-trial participation sold as treatment
- Pressure to pay before medical-record review
- No written description of risks or follow-up
Key public references
- State Council Regulation No. 818Clinical research and clinical translation/application framework, effective 1 May 2026.
- National Health Commission interpretationOfficial questions and answers on the new framework.
- Hainan government overview of frontier biomedical projectsPublic reporting on clinical translation/application projects in Boao Lecheng.